These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19883335)

  • 1. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis.
    Serrano-Fernández P; Möller S; Goertsches R; Fiedler H; Koczan D; Thiesen HJ; Zettl UK
    Autoimmunity; 2010 Mar; 43(2):172-8. PubMed ID: 19883335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers.
    Hilpert J; Beekman JM; Schwenke S; Kowal K; Bauer D; Lampe J; Sandbrink R; Heubach JF; Stürzebecher S; Reischl J
    J Neuroimmunol; 2008 Aug; 199(1-2):115-25. PubMed ID: 18565596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
    Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
    J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients.
    Satoh J; Nakanishi M; Koike F; Onoue H; Aranami T; Yamamoto T; Kawai M; Kikuchi S; Nomura K; Yokoyama K; Ota K; Saito T; Ohta M; Miyake S; Kanda T; Fukazawa T; Yamamura T
    J Neuroimmunol; 2006 May; 174(1-2):108-18. PubMed ID: 16564577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
    Martire S; Navone ND; Montarolo F; Perga S; Bertolotto A
    J Neuroimmunol; 2016 Mar; 292():34-9. PubMed ID: 26943956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
    Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ
    J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
    Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
    J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination.
    Warabi Y; Matsumoto Y; Hayashi H
    J Neurol Sci; 2007 Jan; 252(1):57-61. PubMed ID: 17125797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
    Bitsch A; Bahner D; Wachter C; Elitok E; Bogumil T; Dressel A; Polak T; Tumani H; Weber F; Poser S; Kitze B
    Acta Neurol Scand; 2004 Dec; 110(6):386-92. PubMed ID: 15527451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression analysis of interferon-beta treatment in multiple sclerosis.
    Sellebjerg F; Datta P; Larsen J; Rieneck K; Alsing I; Oturai A; Svejgaard A; Soelberg Sørensen P; Ryder LP
    Mult Scler; 2008 Jun; 14(5):615-21. PubMed ID: 18408020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can blood gene expression predict which patients with multiple sclerosis will respond to interferon?
    Kaminski N; Achiron A
    PLoS Med; 2005 Feb; 2(2):e33; quiz e51. PubMed ID: 15736992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
    Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
    Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.
    Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD
    J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to interferon-beta treatment and results of therapy switching.
    Clerico M; Barbero P; Contessa G; Ferrero C; Durelli L
    J Neurol Sci; 2007 Aug; 259(1-2):104-8. PubMed ID: 17376486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis.
    Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
    Eur Neurol; 2008; 59(3-4):131-5. PubMed ID: 18057899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.